Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification

Similar documents
Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology

Sandler Family Trust. UCSF Medical Center. Headache A Review and Update. Headache The burden. Headache Group, UCSF Disclosure- by proportion*

UCSF Neurology a welcoming place! Migraine Headache clinical classification. Secondary infection hemorrhage trauma tumour CSF pressure change

National Institute for Health Research, UK

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.

How do we treat migraine? New SIGN Guidelines

Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

Overuse of barbiturate and opioid containing medications for primary headache disorders Description

ADVANCES IN MIGRAINE MANAGEMENT

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

Differentiating Migraine from Other Headache Types to Target Treatment Peter J. Goadsby, MD, PhD

Chronic Daily Headaches

Disclosures. Triptans for Kids 5/16/13

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache

Migraine - whats on the horizon

Update on Diagnosis and Management of Migraines

Faculty Disclosures. Learning Objectives

Headache A Practical Approach

Migraine Pathophysiology. Robert E. Shapiro, MD, PhD

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.

Headache. Section 1. Migraine headache. Clinical presentation

Migraine Sandler Family Trust Department of Defence. Cases. Headache Group, UCSF. Disclosure- by proportion*

Headache Pain Generators

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches

Nothing to disclose 3

Clinical Learning Days November 10, 2017

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

Strategies in Migraine Care

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE

Clinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.

ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา

MIGRAINE A MYSTERY HEADACHE

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES

ARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine

Migraine Management. Roger Cady, MD Headache Care Center Springfield, MO

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

HEADACHE PATHOPHYSIOLOGY

A New Era of Migraine Management: The Challenging Landscape in Prevention

10/19/2018. Disclosures MIGRAINE PROPHYLAXIS. Objectives. Definitions Slide. What do you think the aooe stands for at the end of erenumab-aooe?

Headache. Luke Bennetto Consultant Neurologist Engineers House 13 th September 2016

ACUTE TREATMENT FOR MIGRAINE. Cristina Tassorelli

Disclosures. Objectives 6/2/2017

Headache Master School Japan-Osaka 2016 II. Management of refractory headaches Case Presentation 2. SUNCT/SUNA: concept, management and prognosis

ONZETRA XSAIL (sumatriptan) nasal powder

Pediatric Grand Rounds UT Health San Antonio 2/10/2017

Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention

Measure Components Numerator Statement

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD

Headaches in the Pediatric Emergency Dept

The Brainstem Migraine Generator - PET Studies in Migraine (1995) Migraine as a Channelopathy? Research From the Genetic Perspective (1996) Meningeal

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67%

By Nathan Hall Associate Editor

HEADACHE. Primary vs Secondary Headaches SNOOP4. Classification of Primary Headaches. Novel Approaches to Diagnosis and Treatment.

Managing Migraine: Primary Care for Primary Headaches

Headache. Headache Case. Migraine Headache. Eric Kraus, MD. Types» Without aura (common)» With aura (classic)

Migraine: Past, Present and Future Edward O Sullivan September 12 th 2015 Dublin 12/09/2015

2) Headache - Dr. Hawar

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY

SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection

WHY IS MIGRAINE IMPORTANT

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies

Subject: CGRP Inhibitors

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Headache Mary D. Hughes, MD Neuroscience Associates

MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache

Managing Headache in Acute Medicine. Ben Lovell Consultant Physician in Acute Medicine University College London Hospital

Migraine Management. Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN

Management of headache

Pathophysiology of Migraine

MIGRAINES RESEARCH PRESENTATION ONE

Migraine, Tension, and Cluster Headache: Primary Care for Primary Headaches. Jonathon M. Firnhaber, MD, FAAFP

Trigeminal Autonomic Cephalalgias. Disclosures. Objectives 6/20/2018. Rashmi Halker Singh, MD FAHS UCNS Review Course June 2018

Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert

Headache. Steven J. Scrivani, Steven B. Graff-Radford, Shehryar N. Khawaja, and Egilius L. H. Spierings. Contents

Advances in the Treatment of Migraine

DISCLOSURES FUNCTIONS OF THE HYPOTHALAMUS

Louisiana Medicaid. Provider Update. Volume 26, Issue 4 July/August Message from the Medicaid Director Jerry Phillips

Migraine Treatment What you need to know

My patient s pain in the head, is a pain in Greg Jicha, M.D., Ph.D.

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders

Cluster headache (CH): epidemiology, classification and clinical picture

David W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA

Embriologically, The head is formed from the first two cervical segments (except the mandible, which is formed by the third). The first and second

The Clinical Profile of Sumatriptan: Cluster Headache Key Words

Controlling Migraine Pain

FINANCIAL DISCLOSURE. No relevant financial relationships

6/4/2018. Headache. Headaches. Headache. Migraine Headaches. Headache. Red Flag signs and symptoms. Imaging CT without contrast.

Treatment of Primary Headache Syndromes

TABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours

Review of frovatriptan in the treatment of migraine

The trigeminal autonomic cephalalgias (TACs) are a group of. Cluster Headache and Other Trigeminal Autonomic Cephalalgias By Mark Burish, MD, PhD

Emerging Challenges in Primary Care: Brainstorm: A Symposium on Migraine Treatment and Management

Transcription:

28 Primary Care Medicine Principles and Practice 29 October 28 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification Primary 1. 2. Tension-type headache 3. Trigeminal autonomic cephalalgias 3.1 Cluster headache 3.2 Paroxsymal hemicrania 3.3 SUNCT 4. Other Headaches 4.1 Primary Stabbing 4.2 Cough Headache 4.3 Exertional headache 4.4 Sex headache 4.5 Hypnic headache 4.6 Primary Thunderclap Headache 4.7 Hemicrania continua Secondary infection hemorrhage trauma tumour CSF pressure change (Cephalalgia 24;24:1-16) % patients Age Specific Prevalence in the United States 4 35 3 25 2 15 1 5 7.1 5.2 21.5 7.2 27.3 9.7 26 8.1 19.7 12-17 18-29 3-39 4-49 5-59 >6 (Lipton et al., Headache 21; 41:646-657) 7 female male 7.5 2.5 Landmark Study How often are physicians wrong when they diagnose non-migraine in a patient complaining of primary headache? Prospective, open-label study Patients tracked for three months or six attacks Assigned IHS diagnoses by experts % Patients with non-migraine, 1 8 6 4 2 76 (Tepper et al., Headache 24;44:856-864) 18 Migrainous 1

Update in Classification & Diagnosis Pathophysiology Treatment Classification Is there Medication Overuse? Analgesics ten days or more per month Feature full headache Throbbing, unilateral, photophobia, phonophobia, movement effect Is there headache on 15 days or more per month? Episodic Chronic (15+ days/month) with aura without aura International Headache Society Migrene Vanligvis episodisk hodepine (4-72 timer) med visse kjennetegn (& ingen annen årsak): Minst 2 av- ensidig pulserende Moderat til alvorlig Forverrelse ved aktivitet Minst en av- kvalme/brekninger foto/fonofobia (after International Headache Society, 1988) Attacks The Attacks & the Disorder Premonitory symptoms Pain unilateral throbbing movement worse Nausea Sensory sensitivity photophobia phonophobia osmophobia Aura Disorder Repeated attacks < 15 days/month: Episodic 15 days/month: Chronic Family history Triggers (biology) Sleep: missing/excess Food: skipping meals Chemical: alcohol or nitroglycerin Weather Sensory: light, smells Hormonal Stress- relaxation The simple headaches have the same characters, and occur under the same causal conditions of heredity &c, as those in which there are additional other sensory symptoms Gowers 1893 2

Medication Overuse and the evolution of chronic migraine AMPP Sample- 16,339 Progression to Chronic migraine in 2.5% over one year Acetaminophen use does not predict risk Predictors Barbiturates at 5 day/month Opioids at 1 days/month Triptans at 13 days/month NSAIDs are protective if used more than five days a month Update in Classification & Diagnosis Pathophysiology Genetics Aura Pain Treatment Bigal et al., Headache 28;48: in press Genetics of Familial Hemiplegic - an ionopathy aura FHM-I CACNA1A: P/Q voltage-gated Ca 2+ channel chr 19 Ophoff et al. Cell 1996; 87:543 FHM-II ATP1A2: Na + /K + ATPase chr 1q23 De Fusco et al. Nat Gen 23;33:192 FHM-III SCN1A: Voltage-gated Na + channel chr 2 Dichgans et al., Lancet 25;366:371 FHM-IV?:? Silberstein et al., Headache in Clinical Practice 2nd Ed 22 3

Infarctions in the Migrainous Brain? a systems disorder 18Jan6 3Feb6 Kruit et al., Brain 25;128:268 Rozen Cephalalgia 27;27:557-56 (after Goadsby et al., NEJM 22; 346:257-27) The tentorial nerve is a branch of V 1 and the Neck Referred Pain in the Trigeminocervical Complex (TCC) dura mater V ganglion trigeminal nucleus (Feindel et al., Neurology 196;1:555) Cervical input C 1 C 2 }TCC 4

Neck and Headache Cranial Autonomic Features and Experimental Head Pain 8 patients 6 4 2 lacrimation conjunctival injection nasal congestion ptosis miosis Bartsch & Goadsby Current Pain and Headache Reports 23;7:371-376 (Frese et al., Cephalalgia 23;23:67-68) Trigeminal Autonomic Cephalalgias trigeminal-autonomic activation When does migraine start? 1 (Giffin et al., Neurology 23; 6:935-94) dura mater V ganglion pterygopalatine ganglion C1 C2 SSN trigeminal nucleus VAS rating of state of health 8 6 4 2 premonitory headache -1-5 5 1 Time (hours) 5

%patients 1 8 6 4 2 tiredness A11 and the Premonitory Phase stiff neck premonitory headache postdrome yawn polyuria hunger thirst A11 neurons contain tyrosine hydroxylase (green) but not dopamine β-hydroxylase (red) emotional Charbit, Akerman Update in Classification & Diagnosis Pathophysiology Treatment - Current - Recent - Future (Giffin et al., Neurology 23;6:935-94) Therapy in migraine Non-drug Choice of treatment in acute migraine Acute attack treatments Behavioural modification relaxation therapy meditation biofeedback Acupuncture Natural remedies feverfew Non-proven options homeopathy Proven not to work chiropractic osteopathy Non-specific aspirin or acetaminophen NSAIDS ibuprofen naproxen tolfenamic acid opioids Specific ergotamine derivatives ergotamine dihydroergotamine Triptans sumatriptan almotriptan eletriptan frovatriptan naratriptan rizatriptan zolmitriptan 6

Preventives By mechanism Amine modulation 5-HT 2 : cyproheptadine, methysergide β- blockers: propranolol Tricylics: amitriptyline MAOI s: Phenelzine Channel modulation Gabapentin Topiramate Valproate Other - Neurtriceuticals: riboflavin - Botulinum toxin Trigeminovascular System & (Goadsby et al., NEJM 22; 346:257-27) %patients 5 4 3 2 1 Acute Treatment of with Sumatriptan and Naproxen Double-blind randomized parallel group single attack adult migraineurs Placebo Naproxen 5 mg SumaRT 85 mg SUMA+Npx Study I Study II Meta-analysis 34 3 3 25 23 15 16 9 1 9 n = 36 356 361 364 382 364 362 362 799 1751 pain free 2hr pain free 2hr Sumatriptan 1 mg Brandes et al., JAMA 27;297:1443 SumaRT/Nap Ferrari et al., Lancet 21;358:1668 sumatriptan %patients 5 4 3 2 1 Acute Treatment of with Sumatriptan and Naproxen Double-blind randomized parallel group single attack adult migraineurs Placebo Naproxen 5 mg SumaRT 85 mg SUMA+Npx 25 23 19 16 14 1 1 8 7 7 n = 36 356 361 364 382 364 362 362 799 1751 Sustain pain free Sustained pain free Sumatriptan 1 mg Brandes et al., JAMA 27;297:1443 SumaRT/Nap Ferrari et al., Lancet 21;358:1668 sumatriptan AEs Nausea Somnolence Dizziness Paresthesia Dyspepsia 7

Trigeminovascular System & 5-HT 1D CGRP Trigeminal ganglion stimulation increases CGRP in the cranial circulation Hou et al., Brain Res 21;99:112-12 (pmol/l) 12 1 8 6 control VG stimulation 4 2 (Goadsby et al., NEJM 22; 346:257-27) CGRP Substance P CGRP Substance P Cat Human (Goadsby, Edvinsson & Ekman Ann Neurol 1988;23:193) Superior sagittal sinus (SSS) stimulation in cat Neuropeptide changes Calcitonin Gene-Related Peptide (CGRP) and 2 CGRP is released in the cranial circulation in migraine 1 BIBN496BS (olcegepant), a CGRP receptor antagonist, is effective in migraine 2 (pmol/l) 15 1 5 control SSS (pmol/l) 8 6 4 2 7 6 5 4 3 2 1 27 66 placebo BIBN496BS 2.5mg 12 25 CGRP Substance P VIP Neuropeptide Y (Zagami, Goadsby & Edvinsson, Neuropeptides 199;16:69-74) HA response Aes CGRP Sub P control MWA MWOA 1 Goadsby et al., Ann Neurol 199;28:183 2 Olesen et al NEJM 24;35:114 8

CGRP receptor antagonists are effective in acute migraine Double-blind randomized parallel group single attack adult migraineurs Pain Free at 2 hours 5 45 Placebo 4 32 33 3 3 %patients 2 1 14 n = 115 38 4 34 799 1751 3 6 R1 S1 Ho et al., Neurology 28;7:14 telcagepant 9 Ferrari et al., Lancet 21;358:1668 sumatriptan CGRP receptor antagonist telcagepant is effective in the treatment of acute migraine (% patients) 5 4 3 2 1 Double-blind parallel group randomised controlled trial 2 Hour pain free Placebo T-15 T-3 Z5 Z2.5 9.6 17.2 31.3 32.4 29.1 26.9 Ho et al., Ferrari et al., Headache 28;48:S7-S8 Lancet 21;358;1668 7.2 N = 348 333 354 345 553 1135 1219 CGRP receptor antagonist telcagepant is effective in the treatment of acute migraine CGRP receptor antagonist telcagepant is effective in the treatment of acute migraine Sustained pain free (SPF) at 24 and 48 hr 3 SPF 2-24 SPF 2-48 6 Placebo T-15 T-3 Z5 5.7 (% patients) 2.2 2 18 18.2 12.4 1.7 1 7.4 5 3.8 Placebo T-15 T-3 Zolmitriptan-5 (Headache 28;48:S7-S8) (% patients) 4 37.2 32.1 31.4 2 1.4 3.2 4.3 2.1 Aes Triptan-like Aes?Cagepant-class AEs- dry mouth, fatigue (Headache 28;48:S7-S8) 9

and the pons Brainstem activations in right and left-sided headache with PET Left-sided headache Right-sided headache Nitroglycerin-triggered Spontaneous Bahra et al Lancet 21;357:116-117 Afridi et al. Arch Neurol 25;62,127-1275 Afridi et al., Brain 25; 128:932-939 dura mater Vg pterygopalatine ganglion trigeminal nucleus C 2 nausea 1